(Q34987430)

5 August 2017

1 reference

title

Fever and neutropenia in cancer patients: the diagnostic role of cytokines in risk assessment strategies (English)

1 reference

5 August 2017

C S M Oude Nijhuis

1

1 reference

5 August 2017

S M G J Daenen

2

1 reference

5 August 2017

E Vellenga

3

1 reference

5 August 2017

W T A van der Graaf

4

1 reference

5 August 2017

J A Gietema

5

1 reference

5 August 2017

H J M Groen

6

1 reference

5 August 2017

W A Kamps

7

1 reference

5 August 2017

Eveline S J M de Bont

8

1 reference

5 August 2017

publication date

1 November 2002

1 reference

Critical Reviews in Oncology Hematology

5 August 2017

published in

1 reference

5 August 2017

volume

44

1 reference

5 August 2017

issue

2

1 reference

5 August 2017

page(s)

163-174

1 reference

Quantitative Relationships Between Circulating Leukocytes and Infection in Patients with Acute Leukemia

5 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900220-7

7 January 2021

Early lymphopenia after cytotoxic chemotherapy as a risk factor for febrile neutropenia

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900220-7

7 January 2021

Infections in patients with malignant lymphoma treated with combination chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900220-7

7 January 2021

Acute myeloid leukemia in Manitoba. The consequences of standard "7 + 3" remission-induction therapy followed by high dose cytarabine postremission consolidation for myelosuppression, infectious morbidity, and outcome

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900220-7

7 January 2021

Filgrastim in patients with chemotherapy-induced febrile neutropenia. A double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900220-7

7 January 2021

Randomized placebo-controlled trial of granulocyte-macrophage colony-stimulating factor in patients with chemotherapy-related febrile neutropenia.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900220-7

7 January 2021

Effect of chemotherapeutic agents on metabolic and bactericidal activity of polymorphonuclear leukocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900220-7

7 January 2021

Bacteremia due to viridans streptococci in neutropenic patients: a review

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900220-7

7 January 2021

Simple intestinal obstruction causes bacterial translocation in man.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900220-7

7 January 2021

Bacterial translocation and gram-negative bacteremia in patients with hematological malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900220-7

7 January 2021

Clinical presentation of infection in granulocytopenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900220-7

7 January 2021

Fever and infection in leukemic patients.A study of 494 consecutive patients

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900220-7

7 January 2021

Infections in cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900220-7

7 January 2021

The changing pattern of infection in neutropenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900220-7

7 January 2021

Empiric therapy with carbenicillin and gentamicin for febrile patients with cancer and granulocytopenia

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900220-7

7 January 2021

A comparison of outcome from febrile neutropenic episodes in children compared with adults: results from four EORTC studies. International Antimicrobial Therapy Cooperative Group (IATCG) of the European Organization for Research and Treatment of Can

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900220-7

7 January 2021

Self-administered antibiotic therapy for chemotherapy-induced, low-risk febrile neutropenia in patients with nonhematologic neoplasms

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900220-7

7 January 2021

"Low-risk" prediction rule for pediatric oncology patients presenting with fever and neutropenia

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900220-7

7 January 2021

Duration of empiric antibiotic therapy in granulocytopenic patients with cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900220-7

7 January 2021

1997 guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Infectious Diseases Society of America

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900220-7

7 January 2021

Management of fever in patients with cancer and treatment-induced neutropenia

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900220-7

7 January 2021

The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900220-7

7 January 2021

Neutropenic infections: a review of the French Febrile Aplasia Study Group trials in 608 febrile neutropenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900220-7

7 January 2021

Association between antifungal prophylaxis and rate of documented bacteremia in febrile neutropenic cancer patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900220-7

7 January 2021

The changing epidemiology of infections at cancer hospitals

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900220-7

7 January 2021

Staphylococcus epidermidis: an increasing cause of infection in patients with granulocytopenia.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900220-7

7 January 2021

Science and pragmatism in the treatment and prevention of neutropenic infection

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900220-7

7 January 2021

Alpha-hemolytic streptococcal septicemia with severe complications during neutropenia in childhood cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900220-7

7 January 2021

Prevention of infections in the neutropenic patient

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900220-7

7 January 2021

The medical course of cancer patients with fever and neutropenia. Clinical identification of a low-risk subgroup at presentation

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900220-7

7 January 2021

Outbreak of coagulase negative staphylococcus highly resistant to ciprofloxacin in a leukaemia unit

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900220-7

7 January 2021

Outbreak of vancomycin-, ampicillin-, and aminoglycoside-resistant Enterococcus faecium bacteremia in an adult oncology unit

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900220-7

7 January 2021

Vancomycin-resistant Enterococcus faecium bacteremia: risk factors for infection.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900220-7

7 January 2021

Risk factors and attributable mortality associated with superinfections in neutropenic patients with cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900220-7

7 January 2021

Induction of tumor necrosis factor-alpha as a cause of bleomycin-related toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900220-7

7 January 2021

Pyrexia with cytosine arabinoside

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900220-7

7 January 2021

The utility of < or =3-day-old whole-blood platelets in reducing the incidence of febrile nonhemolytic transfusion reactions

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900220-7

7 January 2021

Febrile neutropenia in children

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900220-7

7 January 2021

Outcomes of bacteremia in patients with cancer and neutropenia: observations from two decades of epidemiological and clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900220-7

7 January 2021

Cytokines and the hepatic acute-phase response

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900220-7

7 January 2021

Acute-phase proteins and other systemic responses to inflammation

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900220-7

7 January 2021

Sir Isaac Newton, sepsis, SIRS, and CARS

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900220-7

7 January 2021

Toward a theory regarding the pathogenesis of the systemic inflammatory response syndrome: what we do and do not know about cytokine regulation

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900220-7

7 January 2021

Sepsis: a new hypothesis for pathogenesis of the disease process

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900220-7

7 January 2021

Clinical aspects: from systemic inflammation to 'immunoparalysis'.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900220-7

7 January 2021

Pathophysiologic basis of sepsis: considerations for future strategies of intervention

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900220-7

7 January 2021

Immunomodulatory therapies in sepsis

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900220-7

7 January 2021

Circulating interleukin-1 and tumor necrosis factor in septic shock and experimental endotoxin fever

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900220-7

7 January 2021

Shock and tissue injury induced by recombinant human cachectin

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900220-7

7 January 2021

The macrophage as an effector cell

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900220-7

7 January 2021

Approaching the asymptote? Evolution and revolution in immunology

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900220-7

7 January 2021

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900220-7

1 reference

7 January 2021

Innate immune recognition and control of adaptive immune responses

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900220-7

7 January 2021

Introduction: the role of innate immunity in the adaptive immune response

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900220-7

7 January 2021

The interleukin-1 receptor/Toll-like receptor superfamily: signal generators for pro-inflammatory interleukins and microbial products

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900220-7

7 January 2021

Host defense mechanisms triggered by microbial lipoproteins through toll-like receptors

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900220-7

7 January 2021

Toll-like receptors: molecular mechanisms of the mammalian immune response

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900220-7

7 January 2021

Defective LPS Signaling in C3H/HeJ and C57BL/10ScCr Mice: Mutations in Tlr4 Gene

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900220-7

7 January 2021

Endotoxin-tolerant mice have mutations in Toll-like receptor 4 (Tlr4)

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900220-7

7 January 2021

Toll-like receptor-2 mediates lipopolysaccharide-induced cellular signalling

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900220-7

7 January 2021

Micrococci and peptidoglycan activate TLR2-->MyD88-->IRAK-->TRAF-->NIK-->IKK-->NF-kappaB signal transduction pathway that induces transcription of interleukin-8

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900220-7

7 January 2021

Bacterial lipopolysaccharide activates NF-kappaB through toll-like receptor 4 (TLR-4) in cultured human dermal endothelial cells. Differential expression of TLR-4 and TLR-2 in endothelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900220-7

7 January 2021

Tumour necrosis factor (TNF) gene polymorphism influences TNF-alpha production in lipopolysaccharide (LPS)-stimulated whole blood cell culture in healthy humans

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900220-7

7 January 2021

Cytokine gene polymorphism and heart transplant rejection

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900220-7

7 January 2021

A new promoter polymorphism in the gene of lipopolysaccharide receptor CD14 is associated with expired myocardial infarction in patients with low atherosclerotic risk profile

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900220-7

7 January 2021

Cytokine and cytokine receptor polymorphisms in infectious disease

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900220-7

7 January 2021

IL1B gene polymorphisms influence the course and severity of inflammatory bowel disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900220-7

7 January 2021

Genetic influence on cytokine production and fatal meningococcal disease

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900220-7

7 January 2021

TLR4 mutations are associated with endotoxin hyporesponsiveness in humans

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900220-7

7 January 2021

A novel polymorphism in the toll-like receptor 2 gene and its potential association with staphylococcal infection

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900220-7

7 January 2021

TNF alpha, IL-1 beta and IL-6 plasma levels in neutropenic patients after onset of fever and correlation with the C-reactive protein (CRP) kinetic values

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900220-7

7 January 2021

Intrinsic capacity of monocytes to produce cytokines ex vivo in patients with acute lymphoblastic leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900220-7

7 January 2021

Regulation of the production of pro-inflammatory cytokines and antagonists during chemotherapy-induced neutropenia in patients with haematological malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900220-7

7 January 2021

Cytokine production by peripheral blood monocytes and T cells during haemopoietic recovery after intensive chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900220-7

7 January 2021

Plasma IL-8 and IL-6 levels can be used to define a group with low risk of septicaemia among cancer patients with fever and neutropenia

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900220-7

7 January 2021

Assessment of measuring circulating levels of interleukin-6, interleukin-8, C-reactive protein, soluble Fc gamma receptor type III, and mannose-binding protein in febrile children with cancer and neutropenia

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900220-7

7 January 2021

Interleukin 8 in serum in granulocytopenic patients with infections

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900220-7

7 January 2021

Cytokine and acute-phase reactant levels in serum of children with cancer admitted for fever and neutropenia

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900220-7

7 January 2021

An analysis of interleukin-8, interleukin-6 and C-reactive protein serum concentrations to predict fever, gram-negative bacteremia and complicated infection in neutropenic cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900220-7

7 January 2021

Interleukin-6 and its relationship to C-reactive protein and fever in children with febrile neutropenia

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900220-7

7 January 2021

Diagnostic value of procalcitonin serum levels in neutropenic patients with fever: comparison with interleukin-8.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900220-7

7 January 2021

C-reactive protein, procalcitonin and interleukin-8 in the primary diagnosis of infections in cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900220-7

7 January 2021

Procalcitonin: a diagnostic marker of bacterial infection in neutropenic cancer patients with fever?

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900220-7

7 January 2021

Procalcitonin in paediatric cancer patients: its diagnostic relevance is superior to that of C-reactive protein, interleukin 6, interleukin 8, soluble interleukin 2 receptor and soluble tumour necrosis factor receptor II.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900220-7

7 January 2021

Interleukin-8 in sepsis: relation to shock and inflammatory mediators

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900220-7

7 January 2021

Serum levels of interleukin-6 and acute phase responses

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900220-7

7 January 2021

Cytokine response to infection in patients with acute myelogenous leukaemia following intensive chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900220-7

7 January 2021

Risk assessment in cancer patients with fever and neutropenia: a prospective, two-center validation of a prediction rule

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900220-7

7 January 2021

Home antibiotic therapy for low-risk cancer patients with fever and neutropenia: a pilot study of 30 patients based on a validated prediction rule

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900220-7

7 January 2021

A double-blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900220-7

7 January 2021

Oral versus Intravenous Empirical Antimicrobial Therapy for Fever in Patients with Granulocytopenia Who Are Receiving Cancer Chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900220-7

7 January 2021

Early discharge of low-risk febrile neutropenic children and adolescents with cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900220-7

7 January 2021

Safety and cost effectiveness of early hospital discharge of lower risk children with cancer admitted for fever and neutropenia

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900220-7

7 January 2021

A pilot study of outpatient management of febrile neutropenic children with cancer at low risk of bacteremia

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900220-7

7 January 2021

Outpatient treatment of febrile episodes in low-risk neutropenic patients with cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900220-7

7 January 2021

Feasibility of outpatient management of fever in cancer patients with low-risk neutropenia: results of a prospective randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900220-7

7 January 2021

10.1016/S1040-8428(01)00220-7

Identifiers

DOI

1 reference

5 August 2017

1 reference